Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.
Also called NCT03574363
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 162 participants
- Sponsor
- Registry
-
NCT03574363
-
- Other papers using this trial's data
- Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03574363. Randomized; triple masking; primary purpose treatment. Start 2018-04-25 (actual); primary completion 2020-08-05 (actual). Results posted on 2024-03-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease
- Acronym
- BLOCKCKD
- Condition
- Chronic Kidney Diseases
- Condition
- Hypertension
- Intervention (Drug)
- KBP-5074 0.25 mg tablet
- Intervention (Drug)
- KBP-5074 0.5 mg tablet
- Lead sponsor
- KBP Biosciences
- Collaborator
- Worldwide Clinical Trials
Record details
- Record id
cardio:ct-nct03574363- Content hash
4383ff9e0ede49f4ac6dfb1cc6a00cb2b17367e8b019a8d3b2a2513f4cfe714e